Anfibatide Phase Ib-IIa Clinical Trial

Inclusion Criteria:

1. Aged 18-70 years;
2. Laboratory tests show increase of the markers of myocardial damage (CK-MB,CTnI), orreduction after increase, with at least one values exceeding the 99th percentile ofthe upper limit of the reference value;
3. Ischemia symptoms (ischemic chest pain lasts for over 15 minutes, little release aftertaking nitroglycerin sublingually) or a new myocardial ischemia onelectrocardiogram(ECG), i.e. a new ST-T variation (a new or transient depression of STsegment by over 0.1mV, or T-wave inversion≥0.2mV);
4. Patients receive PCI after coronary angiography;
5. Patients, or their family or guardian give signed informed consent forms.

Exclusion Criteria:

1. Patients with severe unstable hemodynamics who should receive urgent PCI;
2. Patients with untreated hypertension (SBP>180 mmHg or DBP >110mmHg) and hypotensionshock (SBP<90mmHg/80mmHg for over 30min);
3. Investigator considers patients need to use GPIIb/IIIa receptor antagonists during thestudy period;
4. After coronary angiography, the number of stenosed vessels >2；lesions in left mainbranch, severe calcification and artery graft lesions;
5. Patients with heart function in decompensatory phase (Killip grade 3-4) or cardiacshock;
6. Patients with malignant arrhythmia, e.g. the third-degree atrioventricular block,ventricular tachycardia or fibrillation ventricular;
7. Patients with severe hepatic or renal dysfunction, with serum aspartatetransaminase(AST) and alanine transaminase (ALT) exceeding 1.5 times the upper limitof reference values, creatinine clearance <30ml/min or serum creatinine ≥200μmol/L or 2.5mg/dl;
8. Patients who have received PCI in the past six months;
9. Patients who have received coronary artery bypass grafting (CABG) previously;
10. Patients who have received invasive operation in the past 3 months;
11. Patients who have suffered from ischemic stroke or transient ischemic attack (TIA) inthe past 6 months, or patients with past history of hemorrhagic stroke;
12. Patients who need a long-term treatment of oral anticoagulants (such as warfarin);
13. Patients with active peptic ulcer, or other diseases of hemorrhagic tendency;
14. Patients with disease of coagulation disorder;
15. Hematology test shows platelet count <100,000mm3,or hemoglobin<100g/L;
16. Women in pregnant or lactation period, or women of child-bearing age do not takeefficient contraception measures;
17. Patients with an allergic constitution;
18. Patients who is participating in other clinical trials;
19. Patients who do not give a signed informed consent forms;
20. Patients who are not suitable to enroll in the trial according to the investigator'sjudgement.